SONATA: A Single Arm Pilot Trial of a Social Network Intervention

Sponsor
University of Rochester (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05745038
Collaborator
(none)
40
1
1
27
1.5

Study Details

Study Description

Brief Summary

The purpose of this study is to see if a social network support program (SOcial Networks to Activate Trust & Adherence or SONATA) is helpful for older individuals receiving cancer treatment. The SONATA program will last for about 4 months. There are a total of 6 coaching sessions. The first 5 sessions will be held approximately every 1 to 2 weeks. Session 6 or the final session will be held approximately 1 to 2 months after session 5. Each session will last for about 1 to 2 hours.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: SONATA
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Masking Description:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
A Single Arm Pilot Trial of a Social Network Intervention (SONATA) for Older Patients on Oral Anticancer Treatments and Their Network Members
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Jun 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm 1 - SONATA Intervention

Behavioral: SONATA
The SONATA intervention is composed of five components, network diagnostics, network engagement, opportunity creation, skill building and goal-setting, and feedback, that will be audio-recorded and held over six scheduled sessions.

Outcome Measures

Primary Outcome Measures

  1. Feasibility - SONATA Intervention [20 Weeks]

    Number of patients approached who consent

  2. Acceptability- SONATA Intervention [20 Weeks]

    Average general acceptability score using the Theoretical Framework of Acceptability questionnaire. An eight item (range 1 to 5 for each item) psychometrically validated and theoretically informed tool which assesses the following constructs - affective attitude, burden, ethicality, perceived effectiveness, intervention coherence, self-efficacy, opportunity costs, and general acceptability.

Secondary Outcome Measures

  1. Estimate - Social Support [20 Weeks]

    Assessed using the Medical Outcomes Study Social Support Survey. The Medical Outcomes Study Social Support Survey is a 19-item survey (range 1-5 for each item) to assess four domains of emotional/informational support, instrumental support, positive social interaction, and affection; higher scores indicate greater social support. Subjects will be asked about their perceptions of their own social support.

  2. Estimate - Trust in Healthcare Professionals [20 Weeks]

    Assessed using the the Human Connection (THC) Scale. The THC scale is A 16-item scale (range 1 to 4 for each item); higher scores indicate greater trust.

  3. Estimate - Adherence to oral anticancer treatments [20 Weeks]

    Assessed using the Domains of Subjective Extent of Nonadherence (DOSE-Nonadherence). The DOSE-Nonadherence scale is a three-item scale (range from none of the time to every time for each item) with eighteen additional items that assesses reasons for non-adherence.

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Patient

Inclusion Criteria:
  • Age ≥65 years

  • A diagnosis of cancer

  • Planning to initiate or during first three months of oral anticancer treatments

  • Able to identify at least one network member to participate with them

  • Able to speak English

  • Able to provide informed consent

Exclusion Criteria:
  • Any psychiatric or cognitive impairments interfering with participation as determined by the treating oncology team

  • Enrolled on oral anticancer therapeutic trials

Network Members:
Inclusion Criteria:
  1. Age ≥18 years

  2. Identified as a network member by subjects enrolled on the study (up to 10 network members)

  3. Able to provide informed consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Rochester Rochester New York United States 14642

Sponsors and Collaborators

  • University of Rochester

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kah Poh Loh, Assistant Professor, University of Rochester
ClinicalTrials.gov Identifier:
NCT05745038
Other Study ID Numbers:
  • UOCPC22065
First Posted:
Feb 27, 2023
Last Update Posted:
Feb 28, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kah Poh Loh, Assistant Professor, University of Rochester
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 28, 2023